Search | Clinical Trials Finder

Conditions: Sjögren-Larsson Syndrome
Interventions: Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia

Conditions: Autosomal Recessive Ichthyosis
Interventions: KB105, Placebo; Biological · Other
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rancho Santa Margarita, California

Conditions: Burns
Interventions: Fish skin, Cadaver skin; Device
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Genetic Skin Disease, Keratosis Follicularis, Lamellar Ichthyosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ichthyosis, Pruritus
Interventions: Avena Sativa Skincare Regimen; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Lysosomal Storage Disease, Cholesterol Metabolism
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Darier Disease, Hailey-Hailey Disease, Hyperkeratosis, Epidermolytic, Ichthyosis, Ichthyosis, Lamellar, Ichthyosis, X-Linked, Keratoderma
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Netherton Syndrome
Interventions: Pimecrolimus 1% Cream; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Irritable Bowel Syndrome
Interventions: Rimegepant 75 MG [Nurtec]; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: Tauroursodeoxycholic Acid (TUDCA), Sugar Pill (placebo); Drug
Lead sponsor: Robin Goland, MD; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Ichthyosis, Netherton Syndrome
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 1 Year to 60 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York

Conditions: Ichthyosis
Interventions: TMB-001, Matching Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 6 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more

Conditions: Congenital Ichthyosis
Interventions: Isotretinoin, Vehicle; Drug · Other
Lead sponsor: LEO Pharma; Industry
Eligibility: 9 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more

Conditions: Irritable Bowel Syndrome
Interventions: Mindfulness training, Psycho-educational support group for women with IBS; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sjogren-Larsson Syndrome
Interventions: ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Omaha, Nebraska

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Netherton Syndrome
Interventions: QRX003, 4% Lotion; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Rezular 15mg, Placebo, Rezular; Drug
Lead sponsor: AGI Therapeutics, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Irritable Bowel Syndrome
Interventions: Mindfulness based Stress Reduction Training (MBSR); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis, Ichthyosis, Psoriasis
Interventions: Itch Questionnaire and Interview, Stigma Questionnaire and Interview, Cognitive Interview and PROMIS Itch Questionnaire; Other
Lead sponsor: Northwestern University; Other
Eligibility: 0 Years to 17 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Irritable Bowel Syndrome Constipation Predominant
Interventions: ROSE-010, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns

Study of Scaling Disorders and Other Inherited Skin Diseases

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

Study of Inborn Errors of Cholesterol Synthesis and Related Disorders

National Registry for Ichthyosis and Related Disorders

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

Comparison of Rimegepant and Placebo for Pain in IBS

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Defining the Skin and Blood Biomarkers of Ichthyosis

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

The Myelin Disorders Biorepository Project

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

Neuroimaging and Biomarkers in Chronic Visceral Pain

Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients